Active ingredientZanubrutinibCat. No. P-Z007-001CAS 1691249-45-2Family · Pharmaceutical analytical standards
Zanubrutinib
A Bruton's tyrosine kinase (BTK) inhibitor, approved in the United States in 2019 for previously treated mantle cell lymphoma: it blocks a key growth signal in cancerous B cells. This family brings together the active ingredient, labelled standards, nitrosamines and other impurities.
Did you know?It was the first innovative cancer medicine discovered in China to win approval from the US FDA.
Go to the active ingredient →Active ingredientZanubrutinibCat. No. P-Z007-001CAS 1691249-45-2
Isotopically labelled(R)-Zanubrutinib-d5Cat. No. P-Z007-002
Isotopically labelledZanubrutinib d5Cat. No. P-Z007-003
NitrosamineN-Nitroso ZanubrutinibCat. No. P-Z007-004
NitrosamineN-Nitroso N1-Nitroso Zanubrutinib Impurity 1Cat. No. P-Z007-005
NitrosamineN-Nitroso N2-Nitroso Zanubrutinib Impurity 2Cat. No. P-Z007-006
Impurity(R)-ZanubrutinibCat. No. P-Z007-007CAS 1691249-44-1
ImpurityZanubrutinib Impurity 1Cat. No. P-Z007-008CAS 330792-69-3
ImpurityZanubrutinib Impurity 2Cat. No. P-Z007-009CAS 330792-68-2
ImpurityZanubrutinib Impurity 3Cat. No. P-Z007-010CAS 330792-70-6
ImpurityZanubrutinib Impurity 4Cat. No. P-Z007-011CAS 206989-61-9
Impurity4-Phenoxybenzoic acidCat. No. P-Z007-012CAS 2215-77-2
ImpurityZanubrutinib Impurity 5Cat. No. P-Z007-013CAS 2190506-59-1
ImpurityZanubrutinib Impurity 6Cat. No. P-Z007-014CAS 960201-86-9
ImpurityZanubrutinib Impurity 7Cat. No. P-Z007-015CAS 1633352-71-2
ImpurityZanubrutinib Impurity 8Cat. No. P-Z007-016CAS 2190506-55-7
ImpurityZanubrutinib Impurity 9Cat. No. P-Z007-017CAS 2190506-56-8
ImpurityZanubrutinib Impurity 10Cat. No. P-Z007-018CAS 2190506-57-9No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.